Kura Oncology (KURA) Stock Analysis & AI Equity Report
Kura Oncology (KURA) overview
Kura Oncology (KURA) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 67.5m and operating profit of USD -304m; the year-end share price was 10.39 USD and market capitalisation was USD 913m. Kura Oncology is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Kura Oncology's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Kura Oncology
Kura Oncology is a biopharmaceutical company developing and commercializing precision medicines for cancer and other diseases. Its commercial product, KOMZIFTI, is an oral medicine for certain adults with relapsed or refractory acute myeloid leukemia. Its pipeline includes small molecule candidates targeting menin and farnesyl transferase. The company evaluates these candidates alone and with other therapies in oncology and cardiometabolic conditions.
Generate the Kura Oncology report
Kura Oncology is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Kura Oncology and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Kura Oncology
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.